| Popis: |
Background: Association of preoperative peripheral CD4+ T cells percentage and recurrence in colorectal cancer(CRC) remains to be explored. Therefore, we aimed to investigate the association between the preoperative peripheral CD4+ T cells percentage and recurrence in CRC patients. Patients and Methods: Consecutive stage I-III CRC patients undergoing curative resection from January 2010 to July 2016 were identified. Preoperative peripheral CD4+ T cells percentage was measured within one week before surgery. The association between the preoperative CD4+ T cells percentage and recurrence-free survival(RFS) was analyzed. Results: A total of 1248 patients were identified. Normal preoperative CD4+ T cells percentage was present in 47.8% of patients and was associated with a better survival (median RFS: 49 months vs. 43 months in patients with elevated percentage, P=0.33; vs. 46 months in those with reduced percentage, P=0.008). Patients with normal percentage had a 5- year RFS of 80.7% versus 75.4% in those with elevated percentage (hazard ratio[HR]:1.19, 95%CI:0.86-1.66; P=0.31) and 72.1% in those with reduced percentage (HR:1.47, 95%CI:1.12-1.92; P=0.005). In terms of the >2-5 years RFS, it was 93.3% in patients with normal percentage versus 86.2% in those with elevated percentage (HR:1.96, 95% CI:1.12-3.43; P=0.02) and 86.4% in those with reduced percentage (HR:2.02, 95%CI:1.25-3.28; P=0.004). Elevated and reduced preoperative CD4+ T cells percentage remained significant for >2-5 years RFS on multivariate analysis. Conclusion: Preoperative peripheral CD4+ T cells percentage was associated with the recurrence after 2 years following surgery in CRC. Funding Statement: This work was supported by grants from the National Key Research and Development Program of China [2017YFC1309100], the National Natural Scientific Foundation of China [81771912], and the Applied Basic Research Projects of Yunnan Province, China [2018FE001-065 and 2018FE001-251]. Declaration of Interests: The authors declare that they have no potential conflicts of interest. Ethics Approval Statement: This retrospective study was approved by the institutional review board of the Yunnan Cancer Center. The requirement for informed consent was waived by the board, owing to the study's retrospective nature. All the patient data in the survey were anonymized. |
